SPRY2 Loss Enhances ErbB Trafficking and PI3K/AKT Signalling to Drive Human and Mouse Prostate Carcinogenesis

Overview

Journal EMBO Mol Med

Specialty Molecular Biology

Date 2012 Jun 1

PMID 22649008

Citations 30

Authors

Meiling Gao

Rachana Patel

Imran Ahmad

Janis Fleming

Joanne Edwards

Stuart McCracken

Kanagasabai Sahadevan

Morag Seywright

Jim Norman

Owen Sansom

Hing Y Leung

Affiliations

Soon will be listed here.

Abstract

Loss of SPRY2 and activation of receptor tyrosine kinases are common events in prostate cancer (PC). However, the molecular basis of their interaction and clinical impact remains to be fully examined. SPRY2 loss may functionally synergize with aberrant cellular signalling to drive PC and to promote treatment-resistant disease. Here, we report evidence for a positive feedback regulation of the ErbB-PI3K/AKT cascade by SPRY2 loss in in vitro as well as pre-clinical in vivo models and clinical PC. Reduction in SPRY2 expression resulted in hyper-activation of PI3K/AKT signalling to drive proliferation and invasion by enhanced internalization of EGFR/HER2 and their sustained signalling at the early endosome in a PTEN-dependent manner. This involved p38 MAPK activation by PI3K to facilitate clathrin-mediated ErbB receptor endocytosis. Finally, in vitro and in vivo inhibition of PI3K suppressed proliferation and invasion, supporting PI3K/AKT as a target for therapy particularly in patients with PTEN-haploinsufficient-, low SPRY2- and ErbB-expressing tumours. In conclusion, SPRY2 is an important tumour suppressor in PC since its loss drives the PI3K/AKT pathway via functional interaction with the ErbB system.

Citing Articles

Genome-wide CRISPR screens in spheroid culture reveal that the tumor suppressor LKB1 inhibits growth via the PIKFYVE lipid kinase.

Ferrarone J, Thomas J, Unni A, Zheng Y, Nagiec M, Gardner E Proc Natl Acad Sci U S A. 2024; 121(21):e2403685121.

PMID: 38743625 PMC: 11127050. DOI: 10.1073/pnas.2403685121.

Microbiota-derived butyrate restricts tuft cell differentiation via histone deacetylase 3 to modulate intestinal type 2 immunity.

Eshleman E, Rice T, Potter C, Waddell A, Hashimoto-Hill S, Woo V Immunity. 2024; 57(2):319-332.e6.

PMID: 38295798 PMC: 10901458. DOI: 10.1016/j.immuni.2024.01.002.

TRAF7-targeted HOXA5 acts as a tumor suppressor in prostate cancer progression and stemness via transcriptionally activating SPRY2 and regulating MEK/ERK signaling.

Ye J, Liu W, Yu X, Wu L, Chen Z, Yu Y Cell Death Discov. 2023; 9(1):378.

PMID: 37845209 PMC: 10579307. DOI: 10.1038/s41420-023-01675-9.

Examining the Effects of Gestational Physical Activity and Hofbauer Cell Polarization on Angiogenic Factors.

Goudreau A, Tanara L, Tzaneva V, Adamo K Int J Environ Res Public Health. 2023; 20(13).

PMID: 37444145 PMC: 10342061. DOI: 10.3390/ijerph20136298.

Cyclocreatine Suppresses Creatine Metabolism and Impairs Prostate Cancer Progression.

Patel R, Ford C, Rodgers L, Rushworth L, Fleming J, Mui E Cancer Res. 2022; 82(14):2565-2575.

PMID: 35675421 PMC: 9381098. DOI: 10.1158/0008-5472.CAN-21-1301.

References

Sarto P, Balducci E, Balconi G, Fiordaliso F, Merlo L, Tuzzato G . Effects of exercise training on endothelial progenitor cells in patients with chronic heart failure. J Card Fail. 2007; 13(9):701-8. DOI: 10.1016/j.cardfail.2007.06.722. View

Faratian D, Sims A, Mullen P, Kay C, Um I, Langdon S . Sprouty 2 is an independent prognostic factor in breast cancer and may be useful in stratifying patients for trastuzumab therapy. PLoS One. 2011; 6(8):e23772. PMC: 3166119. DOI: 10.1371/journal.pone.0023772. View

Taylor B, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver B . Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010; 18(1):11-22. PMC: 3198787. DOI: 10.1016/j.ccr.2010.05.026. View

Mellinghoff I, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers C . HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell. 2004; 6(5):517-27. DOI: 10.1016/j.ccr.2004.09.031. View

Zhang H, Hu G, Wang H, Sciavolino P, Iler N, Shen M . Heterodimerization of Msx and Dlx homeoproteins results in functional antagonism. Mol Cell Biol. 1997; 17(5):2920-32. PMC: 232144. DOI: 10.1128/MCB.17.5.2920. View

Rubin C, Litvak V, Medvedovsky H, Zwang Y, Lev S, Yarden Y . Sprouty fine-tunes EGF signaling through interlinked positive and negative feedback loops. Curr Biol. 2003; 13(4):297-307. DOI: 10.1016/s0960-9822(03)00053-8. View

Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A . The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci U S A. 2005; 102(3):731-6. PMC: 545522. DOI: 10.1073/pnas.0405495102. View

Carver B, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S . Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011; 19(5):575-86. PMC: 3142785. DOI: 10.1016/j.ccr.2011.04.008. View

Dejana E, Taddei A, Randi A . Foxs and Ets in the transcriptional regulation of endothelial cell differentiation and angiogenesis. Biochim Biophys Acta. 2007; 1775(2):298-312. DOI: 10.1016/j.bbcan.2007.05.003. View

10.

Lesche R, Groszer M, Gao J, Wang Y, Messing A, Sun H . Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis. 2002; 32(2):148-9. DOI: 10.1002/gene.10036. View

11.

Kim H, Taylor L, Bar-Sagi D . Spatial regulation of EGFR signaling by Sprouty2. Curr Biol. 2007; 17(5):455-61. DOI: 10.1016/j.cub.2007.01.059. View

12.

Shim K, Minowada G, Coling D, Martin G . Sprouty2, a mouse deafness gene, regulates cell fate decisions in the auditory sensory epithelium by antagonizing FGF signaling. Dev Cell. 2005; 8(4):553-64. DOI: 10.1016/j.devcel.2005.02.009. View

13.

Baluk P, Fuxe J, Hashizume H, Romano T, Lashnits E, Butz S . Functionally specialized junctions between endothelial cells of lymphatic vessels. J Exp Med. 2007; 204(10):2349-62. PMC: 2118470. DOI: 10.1084/jem.20062596. View

14.

Hsieh A, Costa M, Zollo O, Davis C, Feldman M, Testa J . Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell. 2010; 17(3):249-61. PMC: 2901095. DOI: 10.1016/j.ccr.2010.01.021. View

15.

Andrechek E, Hardy W, Siegel P, Rudnicki M, Cardiff R, Muller W . Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. Proc Natl Acad Sci U S A. 2000; 97(7):3444-9. PMC: 16259. DOI: 10.1073/pnas.97.7.3444. View

16.

Kim M, Cardiff R, Desai N, Banach-Petrosky W, Parsons R, Shen M . Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci U S A. 2002; 99(5):2884-9. PMC: 122442. DOI: 10.1073/pnas.042688999. View

17.

Kim J, Eltoum I, Roh M, Wang J, Abdulkadir S . Interactions between cells with distinct mutations in c-MYC and Pten in prostate cancer. PLoS Genet. 2009; 5(7):e1000542. PMC: 2697385. DOI: 10.1371/journal.pgen.1000542. View

18.

Traish A, Morgentaler A . Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth. Br J Cancer. 2009; 101(12):1949-56. PMC: 2795439. DOI: 10.1038/sj.bjc.6605376. View

19.

Gumerlock P, Chi S, Shi X, Voeller H, Jacobson J, Gelmann E . p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. The Cooperative Prostate Network. J Natl Cancer Inst. 1997; 89(1):66-71. DOI: 10.1093/jnci/89.1.66. View

20.

Kawakami Y, Kubota N, Ekuni N, Suzuki-Yamamoto T, Kimoto M, Yamashita H . Tumor-suppressive lipoxygenases inhibit the expression of c-myc mRNA coding region determinant-binding protein/insulin-like growth factor II mRNA-binding protein 1 in human prostate carcinoma PC-3 cells. Biosci Biotechnol Biochem. 2009; 73(8):1811-7. DOI: 10.1271/bbb.90185. View